1229 related articles for article (PubMed ID: 25301630)
1. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution.
de Bruin EC; McGranahan N; Mitter R; Salm M; Wedge DC; Yates L; Jamal-Hanjani M; Shafi S; Murugaesu N; Rowan AJ; Grönroos E; Muhammad MA; Horswell S; Gerlinger M; Varela I; Jones D; Marshall J; Voet T; Van Loo P; Rassl DM; Rintoul RC; Janes SM; Lee SM; Forster M; Ahmad T; Lawrence D; Falzon M; Capitanio A; Harkins TT; Lee CC; Tom W; Teefe E; Chen SC; Begum S; Rabinowitz A; Phillimore B; Spencer-Dene B; Stamp G; Szallasi Z; Matthews N; Stewart A; Campbell P; Swanton C
Science; 2014 Oct; 346(6206):251-6. PubMed ID: 25301630
[TBL] [Abstract][Full Text] [Related]
2. Tracking the Evolution of Non-Small-Cell Lung Cancer.
Jamal-Hanjani M; Wilson GA; McGranahan N; Birkbak NJ; Watkins TBK; Veeriah S; Shafi S; Johnson DH; Mitter R; Rosenthal R; Salm M; Horswell S; Escudero M; Matthews N; Rowan A; Chambers T; Moore DA; Turajlic S; Xu H; Lee SM; Forster MD; Ahmad T; Hiley CT; Abbosh C; Falzon M; Borg E; Marafioti T; Lawrence D; Hayward M; Kolvekar S; Panagiotopoulos N; Janes SM; Thakrar R; Ahmed A; Blackhall F; Summers Y; Shah R; Joseph L; Quinn AM; Crosbie PA; Naidu B; Middleton G; Langman G; Trotter S; Nicolson M; Remmen H; Kerr K; Chetty M; Gomersall L; Fennell DA; Nakas A; Rathinam S; Anand G; Khan S; Russell P; Ezhil V; Ismail B; Irvin-Sellers M; Prakash V; Lester JF; Kornaszewska M; Attanoos R; Adams H; Davies H; Dentro S; Taniere P; O'Sullivan B; Lowe HL; Hartley JA; Iles N; Bell H; Ngai Y; Shaw JA; Herrero J; Szallasi Z; Schwarz RF; Stewart A; Quezada SA; Le Quesne J; Van Loo P; Dive C; Hackshaw A; Swanton C;
N Engl J Med; 2017 Jun; 376(22):2109-2121. PubMed ID: 28445112
[TBL] [Abstract][Full Text] [Related]
3. Lung cancer: Heterogeneity in space and time.
Errico A
Nat Rev Clin Oncol; 2014 Dec; 11(12):684. PubMed ID: 25348786
[No Abstract] [Full Text] [Related]
4. Cancer. Attack of the clones.
Govindan R
Science; 2014 Oct; 346(6206):169-70. PubMed ID: 25301605
[No Abstract] [Full Text] [Related]
5. Multiregion sequencing reveals the intratumor heterogeneity of driver mutations in TP53-driven non-small cell lung cancer.
Zhang LL; Kan M; Zhang MM; Yu SS; Xie HJ; Gu ZH; Wang HN; Zhao SX; Zhou GB; Song HD; Zheng CX
Int J Cancer; 2017 Jan; 140(1):103-108. PubMed ID: 27646734
[TBL] [Abstract][Full Text] [Related]
6. A 12-gene genomic instability signature predicts clinical outcomes in multiple cancer types.
Mettu RK; Wan YW; Habermann JK; Ried T; Guo NL
Int J Biol Markers; 2010; 25(4):219-28. PubMed ID: 21161944
[TBL] [Abstract][Full Text] [Related]
7. The evolution of lung cancer and impact of subclonal selection in TRACERx.
Frankell AM; Dietzen M; Al Bakir M; Lim EL; Karasaki T; Ward S; Veeriah S; Colliver E; Huebner A; Bunkum A; Hill MS; Grigoriadis K; Moore DA; Black JRM; Liu WK; Thol K; Pich O; Watkins TBK; Naceur-Lombardelli C; Cook DE; Salgado R; Wilson GA; Bailey C; Angelova M; Bentham R; Martínez-Ruiz C; Abbosh C; Nicholson AG; Le Quesne J; Biswas D; Rosenthal R; Puttick C; Hessey S; Lee C; Prymas P; Toncheva A; Smith J; Xing W; Nicod J; Price G; Kerr KM; Naidu B; Middleton G; Blyth KG; Fennell DA; Forster MD; Lee SM; Falzon M; Hewish M; Shackcloth MJ; Lim E; Benafif S; Russell P; Boleti E; Krebs MG; Lester JF; Papadatos-Pastos D; Ahmad T; Thakrar RM; Lawrence D; Navani N; Janes SM; Dive C; Blackhall FH; Summers Y; Cave J; Marafioti T; Herrero J; Quezada SA; Peggs KS; Schwarz RF; Van Loo P; Miedema DM; Birkbak NJ; Hiley CT; Hackshaw A; Zaccaria S; ; Jamal-Hanjani M; McGranahan N; Swanton C
Nature; 2023 Apr; 616(7957):525-533. PubMed ID: 37046096
[TBL] [Abstract][Full Text] [Related]
8. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer.
Westcott PM; Halliwill KD; To MD; Rashid M; Rust AG; Keane TM; Delrosario R; Jen KY; Gurley KE; Kemp CJ; Fredlund E; Quigley DA; Adams DJ; Balmain A
Nature; 2015 Jan; 517(7535):489-92. PubMed ID: 25363767
[TBL] [Abstract][Full Text] [Related]
9. Tumour evolution: clonal ancestry in lung cancer.
Alderton GK
Nat Rev Cancer; 2014 Dec; 14(12):763. PubMed ID: 25568921
[No Abstract] [Full Text] [Related]
10. The genomic landscape of nonsmall cell lung carcinoma in never smokers.
Boeckx B; Shahi RB; Smeets D; De Brakeleer S; Decoster L; Van Brussel T; Galdermans D; Vercauter P; Decoster L; Alexander P; Berchem G; Ocak S; Vuylsteke P; Deschepper K; Lambrechts M; Cappoen N; Teugels E; Lambrechts D; De Greve J
Int J Cancer; 2020 Jun; 146(11):3207-3218. PubMed ID: 31745979
[TBL] [Abstract][Full Text] [Related]
11. APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer.
Wang S; Jia M; He Z; Liu XS
Oncogene; 2018 Jul; 37(29):3924-3936. PubMed ID: 29695832
[TBL] [Abstract][Full Text] [Related]
12. APOBEC mutagenesis and selection for NFE2L2 contribute to the origin of lung squamous-cell carcinoma.
Cannataro VL; Kudalkar S; Dasari K; Gaffney SG; Lazowski HM; Jackson LK; Yildiz I; Das RK; Gould Rothberg BE; Anderson KS; Townsend JP
Lung Cancer; 2022 Sep; 171():34-41. PubMed ID: 35872531
[TBL] [Abstract][Full Text] [Related]
13. APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity.
Swanton C; McGranahan N; Starrett GJ; Harris RS
Cancer Discov; 2015 Jul; 5(7):704-12. PubMed ID: 26091828
[TBL] [Abstract][Full Text] [Related]
14. Generation of Genomic Alteration from Cytidine Deamination.
Liu X; Meng FL
Adv Exp Med Biol; 2018; 1044():49-64. PubMed ID: 29956291
[TBL] [Abstract][Full Text] [Related]
15. APOBEC Mutagenesis and Copy-Number Alterations Are Drivers of Proteogenomic Tumor Evolution and Heterogeneity in Metastatic Thoracic Tumors.
Roper N; Gao S; Maity TK; Banday AR; Zhang X; Venugopalan A; Cultraro CM; Patidar R; Sindiri S; Brown AL; Goncearenco A; Panchenko AR; Biswas R; Thomas A; Rajan A; Carter CA; Kleiner DE; Hewitt SM; Khan J; Prokunina-Olsson L; Guha U
Cell Rep; 2019 Mar; 26(10):2651-2666.e6. PubMed ID: 30840888
[TBL] [Abstract][Full Text] [Related]
16. Smoking-related genomic signatures in non-small cell lung cancer.
Massion PP; Zou Y; Chen H; Jiang A; Coulson P; Amos CI; Wu X; Wistuba I; Wei Q; Shyr Y; Spitz MR
Am J Respir Crit Care Med; 2008 Dec; 178(11):1164-72. PubMed ID: 18776155
[TBL] [Abstract][Full Text] [Related]
17. Whole genome copy number analyses reveal a highly aberrant genome in TP53 mutant lung adenocarcinoma tumors.
Bjaanæs MM; Nilsen G; Halvorsen AR; Russnes HG; Solberg S; Jørgensen L; Brustugun OT; Lingjærde OC; Helland Å
BMC Cancer; 2021 Oct; 21(1):1089. PubMed ID: 34625038
[TBL] [Abstract][Full Text] [Related]
18. LINE-1 hypomethylation is associated to specific clinico-pathological features in Stage I non-small cell lung cancer.
Imperatori A; Sahnane N; Rotolo N; Franzi F; Nardecchia E; Libera L; Romualdi C; Cattoni M; Sessa F; Dominioni L; Furlan D
Lung Cancer; 2017 Jun; 108():83-89. PubMed ID: 28625654
[TBL] [Abstract][Full Text] [Related]
19. The influence of TP53 mutations on the prognosis of patients with early stage non-small cell lung cancer may depend on the intratumor heterogeneity of the mutations.
Lee SY; Jeon HS; Hwangbo Y; Jeong JY; Park JY; Lee EJ; Jin G; Shin KM; Yoo SS; Lee J; Lee EB; Cha SI; Kim CH; Park JY
Mol Carcinog; 2015 Feb; 54(2):93-101. PubMed ID: 24038464
[TBL] [Abstract][Full Text] [Related]
20. ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations.
Peretti U; Ferrara R; Pilotto S; Kinspergher S; Caccese M; Santo A; Brunelli M; Caliò A; Carbognin L; Sperduti I; Garassino M; Chilosi M; Scarpa A; Tortora G; Bria E
Respir Res; 2016 Aug; 17(1):105. PubMed ID: 27561692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
